Delivery Order SPE2DB24D9238-SPE2DB25FDRBA
- Not listed
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $3,094.80 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery at its Park Ridge location with an ultimate completion date of October 2, 2025. This delivery order was issued without a set-aside designation, leveraging the company's competitive capabilities...
- The Defense Logistics Agency awarded a $1,547.40 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately $500 million...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $2,321.10 by the Defense Logistics Agency (DLA) on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract, awarded without set-aside designation, carries a firm fixed-price structure with an ultimate completion date of September 18, 2025. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. This firm fixed-price delivery order, issued on September 10, 2025, is scheduled for ultimate completion by October 1, 2025, with performance taking place at the awardee's Park Ridge facility. The contract was awarded without a set-aside designation,...
- The U.S. Defense Logistics Agency Medical Supply Chain issued a firm fixed-price delivery order valued at $1,712.22 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml. The award was made on July 30, 2025, with an ultimate completion date of August 13, 2025, and will be performed at the vendor's location in Park Ridge, Illinois. This delivery order carries no set-aside designation and represents a discrete purchase under DMS Pharmaceutical Group's larger indefinite delivery...
- The Defense Logistics Agency awarded a $4,642.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The contract, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for $6,189.60 to supply Xolair 150 mg/ml syringes. The delivery order, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, carries firm fixed pricing and does not include a set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award Indefinite...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery at its location in Park Ridge, IL. This delivery order was issued without a set-aside designation and carries an ultimate completion date of September 16, 2025. The award represents a...
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order for XOLAIR 150 MG/ML syringes valued at $3,094.80. The contract, which was awarded on September 8, 2025, with an ultimate completion date of September 29, 2025, carries firm fixed-price terms and does not utilize a set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,284.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/1.2 ml powder vials. The contract is firm fixed-price with an ultimate completion date of September 9, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA...
- SPE2DB24D9238Indefinite Delivery Contract
- SPE2DB24D9238-SPE2DB25FDRBADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $13,926.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, issued on September 12, 2025, with an ultimate completion date of October 3, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The contract carries no set-aside designation, allowing the vendor to compete on an unrestricted basis despite its small business status. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, holding a significant single-award IDC with the DLA valued at $499,999,999 through November 2026. This overarching contract enables the agency to issue delivery orders for comprehensive pharmaceutical products supporting military health facilities worldwide, including branded and generic prescription drugs, biologics, and medical consumables. Xolair, a biologic medication used primarily in the treatment of moderate-to-severe asthma and chronic urticaria, falls within the vendor's extensive portfolio of specialty pharmaceutical products distributed to Department of Defense healthcare sites.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.9k | 9/12/25 |